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1. Introduction  
Onychomycosis is the fungal infection of the nail, that can be caused by dermatophytes, 
Candida sp. or non-dermatophyte moulds (NDM). The term tinea unguium is a specific form 
of onychomycosis caused only by dermatophytes and thus, should not be regarded as 
synonymous. (Odds et al., 1992) 
On the other hand, the term leukonychia or white nails has a varied etiology, it can be 
congenital or acquired, infectious and non-infectious. In the case of onychomycosis, the 
diseased nail plate has an external origin, which is the fungal invasion that affects 
secondarily the normally formed nail. This is also known as fungal or mycotic leukonychia 
(Baran et al. 1994). 
Onychomycosis, with all the different clinical presentations, is responsible for about 50% of 
all dystrophic nails and has a prevalence of 3-10% in the general population. Frequency also 
depends, on geographic conditions and age groups, with an increase in the prevalence in the 
elderly. It is now becoming more evident that immunosuppressed patients, particularly 
those living with HIV infection, are at a higher risk of presenting this nail fungal infection, 
and any clinical presentation is higher compared to the same age group of the general 
population ( Denning et al. 1995; Moreno-Coutiño et al., 2011; Winberg et al. 2003). 
The first classification of onychomycosis was proposed by Zaias,  and is based on the clinical 
appearance of the nails (Zaias, 1972). He described four clinical types: [1] distal subungual 
onychomycosis (DSO), [2] white superficial onychomycosis (WSO), [3] proximal subungual 
onychomycosis (PSO) and [4] Candida sp. onychomycosis. Since the publication of this 
paper, some modifications have been added. In 1998, Baran et al. proposed [I] distal and 
lateral subungual onychomycosis (DLSO), [II] superficial onychomycosis, [III] proximal 
subungual onychomycosis (PSO), [IV] endonyx onychomycosis and [V] total dystrophic 
onychomycosis (TDO). The most used these days is the following: DLSO, white superficial 
onychomycosis (WSO), PSO, Candida onychomycosis (paronychia) and TDO (Table 1) , 
(Baran et al 1998). WSO and PSO are also known as mycotic leukonychia. Further 
subdivisions are included in almost all the categories, and will be discussed further when 
necessary (Gupta & Summerbell, 1999).  
In 1976, English described a classification based on etiology, instead of the clinical aspect of 
the fungal invasion. The categories are: (a) dermatophytes causing tinea unguium, (b) moulds 
(Non-dermatophyte moulds [NDM]) and (c) yeasts (Crozier et al. 1979). At this moment, the 
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Distal and lateral subungual onychomycosis (DLSO) 
Proximal white subungual onychomycosis (PWSO) 
Superficial white onychomycosis (SWO) 
Total dystrophic onychomycosis (TDO) 
Candida paronychia 
Table 1. Current clinical classification 
current classifications are not being specific enough to describe the clinical picture, etiology 
or prognostic factors regarding response to treatment (Grossman & Scher, 1990). Fungal or 
mycotic leukonychia was rather infrequent until the AIDS pandemia. PWSO is the least 
common form of onychomycosis in the HIV negative population, and DLSO is the most 
prevalent form of onychomycosis in patients living with HIV/AIDS. Since the identification 
of this disease in the 1980´s, many case reports and studies have been done. Although 
onychomycosis is not considered an AIDS-defining illness, and its presence is not useful for 
clinical classification, the presence of fungal leukonychia should alert the physician about 
possible immunosuppression. However, PSWO heralds advanced HIV disease and can be 
an early clinical marker of HIV infection (Chang & Arenas, 1995). 
For some patients and even some physicians, onychomycosis is not a relevant medical 
condition. Nonetheless, it can have an important impact on the quality of life, particularly in 
patients living with HIV/AIDS. This group of patients commonly presents fingernail 
involvement as well as toenail infection more frequently than the non-immunosuppressed. 
This fact has negative effect on the quality of life because, unlike feet, hands are exposed all 
the time (Millikan et al., 1999). Embarrassment, problems in the work area, including 
unemployment, reduction in social activities, alienation, fear of spreading the disease to 
others and pain, are the most common complaints (Drake et al., 1999). 
In the WHO clinical classification of HIV-associated disease is designed to be used in 
patients with confirmed HIV infection, the fungal nail infections are considered in clinical 
stage 2 (mild disease) that usually present with >450 CD4 cell count. 
2. Epidemiology 
According to the WHO, in 2009 the number of people living with HIV was 33.3 million 
worldwide. During 2009, 2.6 million were infected, and these numbers continue to rise 
(World Health Organization [WHO], 2009).  
The incidence of all clinical forms of onychomycosis in HIV infected patients has slight 
variations in different countries, as has been noted in several reports. For instance, in Canada 
as well as in India, the incidence is 24%, 30% in France, and 20 % in Mexico.  
Onychomycosis in open population in the USA is between 2-3%, 8.4% in Finland, 2.7% in 
the UK and 2.6% in Spain. Nonetheless, the Achilles project, the largest study on the 
prevalence of foot diseases in Europe found a much higher number, of 29.6%. In México, the 
incidence reported is 30%, but a recent national survey has showed a suspected frequency of 
48% (Arenas, Bonifaz, et al. 2010). These reports include all age groups, and the numbers are 
similar to those reported in the HIV infected population, but if we separate the data by age 
group, the HIV group is younger for such an incidence compared to open population. 
Specific epidemiologic data about mycotic leukonychia (WSO and PWSO) is scarce. It was 
only after the HIV pandemia developed that case reports were published, in the late 80´s. 
Before that time, the clinical presentation of fungal leukonychia was infrequent and the 
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fungi isolated were mostly NDM. WSO in general population has a prevalence of 1-2% and 
PWSO 8.3%. 
For HIV positive population in 1998, Cribier et al. reported a prevalence of 8.5% for fungal 
leukonychias, Piraccini et al. of 9.5%, and Dompmartin et al. of 8%. This small numbers, 
contrast with other series such as the one published by Ravnborg et al. where 90% of their 
cases of onychomycosis, were clinically classified as PWSO (Ravnborg et al., 1998). In a 
report of patients from Canada and Brazil, WSO had prevalence of 3.3% and 5% and for 
PWSO of 1.5% and 3% respectively. The overall prevalence for onychomycosis in HIV 
infected patients was reported of 23.2% (Arenas et al., 2010; Cribier et al., 1998; Dompmartin 
et al., 1990; Gupta et al. 2000; Noppakun & Head, 1986; Weismann et al. 1988). 
Among patients living with HIV/AIDS, onychomycosis is the fourth most common 
dermatological manifestation, with an incidence of 10-44%, and an estimated prevalence 15-
40%. They are clinically more aggressive with rapid spread in finger or toenails (Herranz et 
al., 1997) particularly in those with a cell count of 450 CD4 or lower. Some authors even 
report below 370 CD4. This finding suggests that the degree of immunosuppression plays 
an important role in the development of the disease. On the other hand, a Spanish study on 
prevalence and characteristics of dermatological diseases in HIV infected patients reported 
onychomycosis as the third most  common dermatoses, particularly the DLSO clinical form, 
and found no statistical difference in the incidence between patients with <200 CD4 or ≥200 
CD4 (Blanes et al., 2010; Piraccini & Tosti, 2004; Singh et al., 2009).  
The age group most affected is the one of young adults, between 30 and 40 years of age 
(mean 36.6), because they are the majority of the HIV infected patients. As the HIV infection 
in many countries still predominates in the male gender, these comprise the majority of the 
patients with diagnosis of onychomycosis, with a sex ratio of 9:1 compared to females. 
However, the male:female ratio varies between countries. Where the infection rates are 
almost equal between genders, the ratio has been reported of 2:1.  
Children in general, are a very low risk group for onychomycosis. The highest prevalence is 
reported in Latin American Countries as Mexico and Guatemala. In the former country is 
mainly observed in adolescents of both genders (Gupta et al. 1997; Vásquez del Mercado & 
Arenas, 2008).  
The incidence reported varies from 0% in Wales, Finland and USA, 0.16% in Canada and 
2.6% in Guatemala. This is thought to be because children have a reduced exposure to 
fungus, they have spent less time in contaminated environments, their nails grow faster, the 
nail surface is smaller so it provides less space for invasion, and they also have lower 
prevalence of tinea pedis which has been acknowledged as an important risk factor. There 
are no published series of HIV infected children regarding leukonychia.  
The multiple studies published in adult population prove that the causative agents of fungal 
leukonychia, that include dermatophytes, Candida spp. and NDM remain the same despite 
the globalization of infectious diseases and that the worldwide prevalence of all superficial 
mycotic infections has been rising during the last decade, reaching up to 20-25% of the 
general population. They have a worldwide distribution, predominate in toenails, 
particularly caused by moulds. In fingernails, the association of constant contact with water 
and detergent damages the cuticle, facilitating fungal invasion of the nail plate and the main 
etiological agent is Candida sp. This is frequently seen in women involved in household 
activities (Arenas, 1990).  
The most reported dermatophytes isolated are Trichophyton rubrum, T. mentagrophytes. 
Among the isolated NDM were: Aspergillus niger, Cladoaporium spp, Scytalidium hyalinum, 
Penicillium spp and Gymnoascus dankaliensis, and Candida spp. (Sujushe et al., 2007).  
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The fungi capable of causing nail plate infection are ubiquitous. Tropical climate, heat and 
local humidity favor their development (between 25-28°C), as well as personal factors such 
as occlusive footwear, excessive sweating of feet, nail trauma, nail growth rate and in these 
particular cases, immunosuppression (table 2) (Elewski, 1998). The poor prognostic factors 
are: nail plate involvement of more than 50%, matrix area involvement, significant lateral 
disease, subungual hyperkeratosis >2mm, the presence of longitudinal streaks in the nail, 
NDM documented infection as well as diminished peripheral circulation. These infections 
have low tendency to self limitation (Scher et al., 2007; Havlickova et al.,  2008).  
 
 
<450 CD4/L cell count 
No ARV therapy 
Occlusive footwear 
Repeated trauma in nail 
apparatus 
Tinea pedis, tinea cruris or 
corporis 
Direct family members with 
onychomycosis 
Table 2. Risk factors 
3. Etiology and pathogenesis 
Traditionally it is thought that the route of infection for fungal leukonychia is the dorsal 
aspect of the nail plate in the case of WSO and the PWSO is believed to originate from 
invasion through the proximal nail fold. However, controversy exists in both cases and will 
be further discussed. 
The classic presentation of WSO initiates as white superficial patches without distinct edges 
that may gradually coalesce and invade the entire nail plate. At this point, the surface of the 
nail becomes uneven, porous and crumbles. Trichophyton mentagrophytes var. interdigitale is 
responsible for 90 % of the infections, associated or not to tinea pedis.  
Other common pathogens that cause WSO are T. rubrum and non dermatophyte moulds 
(NDM) such as Aspergillus spp., Fusarium spp., and Acremonium spp. (Baran et al. 2007; Baran 
et al., 2004) 
According to Baran et al, WSO can be subdivided into: 
1. Classical WSO with superficial invasion of the visible portion of the nail plate. 
Leukonychia presents as patches or striate superficial bands, alternated with normal 
color and appearance of the nail plate. 
2. Clinically similar to the first form described, the difference is that this one originates 
beneath the proximal nail fold due to invasion of the ventral aspect of its eponiquial 
segment. Usually involves several toenails simultaneously. This form may be confused 
with PSWO and is frequently seen in the context of HIV infection.  
3. WSO with deep invasion of the nail plate that progressed to deep penetration from the 
superficial aspect of the nail plate with possible extension beneath the nail fold.  
4. Mixed forms, where WSO and other forms of onychomycosis coexist independently. 
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Several factors are involved in the development of SWO. The fungus must possess 
keratinolytic enzymes that enable it to penetrate the hard keratins of the nail plate. The 
invasion starts as superficial, but depending on host’s and parasites characteristics, the 
entire depth and/or length of the nail plate may be involved. One of the most important 
host factors that influence the evolution of the disease is the decreased immune function 
against the fungus mainly because of the HIV infection, although chemotherapy and 
systemic steroid therapy may also be accounted responsible in other group of patients. It has 
been proposed that the low CD4 count affects the resistance to ordinary pathogens even in 
the avascular nail plate.  
Another factor is the genetic background. By genetic predisposition, the nail surface is 
poorly resistant to the fungal penetration and invasion, so WSO can be considered an 
autosomal dominant disease. And, of course, as in any other type of onychomycosis, local 
humidity by occlusive shoes, nail plate thickness and nail plate growth rate, influence the 
development of the disease (Piraccini & Tosti, 2004).  
PWSO is generally caused by dermatophytes, and is seen mainly in immunocompromised 
patients, especially when many nails are involved. When associated to paronychia, the 
infectious agent is generally a NMD. The dermatophyte Trichophyton rubrum is the most 
common isolated infectious agent. Other dermatophytes that have been reported to cause 
PWSO are T. mentagrophytes and even Microsporum canis. Among the NDM reported are 
Aspergillus niger, A. sclerotiorum, and A. flavus. (Table 3) (Weinberg, et al.,  1999). 
 
 
T. rubrum PWSO 
T. mentagrophytes var. 
interdigitale 
SWO 
Microsporum canis PWSO
Aspergillus spp SWO 
Fusarium spp. SWO 
Acremonium spp. SWO 
Candida spp PWSO
Table 3. Most frequently isolated fungus 
The most accepted theory for the route of infection in PWSO is the one that states that 
apparently, the stratum corneum on the ventral aspect of the proximal nail fold is the 
primary site of fungal invasion. When the fungus reaches the matrix, it mainly spreads to 
the lower part of the nail plate. However, Baran et al. have proposed a new theory. The 
fungal infection that initiates in the lunula region could be secondary to endogenous 
reactivation or auto-reinfection from a deeper site instead than from an external source. 
Based on evidence that dermatophyte antigenemia exists in patients with foot infections, 
they mention the possibility of reactivation after initial spread and sequestration with 
systemic dissemination either through retrograde lymphatic or hematogenous spread into 
the nail matrix and nail bed.  Despite the known fact that dermatophytes are normally 
confined to the keratinous components of the skin and its appendages, some studies have 
proven that dermatophytes can survive in the bloodstream and lymphatic tissues and this, 
has led to think that this could explain the peculiar clinical manifestation and evolution of 
HIV-infected patients that present with PWSO.  
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This systemic spread theory is supported by the observation of multiple leukonychial 
transversal bands frequently seen in patients living with HIV/AIDS and PWSO. These 
bands are separated by histologically normal and micologically negative nail (Baran et al., 
2005).   
Although poorly understood, as with any other infectious agent, it is clear that the 
immunological state of the patient plays an important role in the development and 
evolution of the onychomycosis. Immunological defects other than those affecting T-
lymphocyte function, such as defective neutrophil chemotaxis, have also been associated 
with the appearance of PWSO. 
It has been established that patients with HIV and dermatophytic infection are predisposed 
to suffer a chronic course and even, although very rare, to evolve to invasive disease. The 
impairment of cell-mediated immunity has been related with these conditions. Changes in 
the balance between TH1 and TH2 immune responses have been implicated in the 
progression of dermatophytosis associated to HIV infection (Woodfolk, 2005).  
Diverse fungal species as dermatophytes and opportunistic fungi, are frequently cultured 
from the samples obtained from these patients. The most common remain T. rubrum and 
T. mentagrophytes despite their immunocompromised state and the globalization of 
infections.  
This population frequently presents in the same nail plate PSWO associated to WSO. This 
may be initiated from the distal surface and the proximal nail fold independent one from the 
other. This is difficult to assess. Regardless of how or where the infection started, the fungus 
may spread to affect either or both the dorsal and ventral nail surfaces. This may even result 
eventually in a modification of the clinical presentation. That is, PWSO may turn into a 
DLSO or TDO. The same is true for WSO, which may convert to PSWO or any other 
category (Baran at al., 2007; Baran at al., 2004; Hogan, 2006).  
Regarding identified risk factors, trauma was the major predisposing factor, followed by 
diabetes mellitus and peripheral vascular disease. Strong association to tinea pedis exists, as 
toenails are more commonly affected (Surjushe et al., 2007).  
4. Clinical signs 
The clinical characteristics of onychomycosis in patients living with HIV are commonly 
recognized because of the extension, rapid evolution and limited response to treatment. 
(Table 4 & 5). 
 
 
Usually more than 3 nails involved 
Rapid evolution 
Mostly toenails 
Leukonychia or DLSO 
<450 CD4/L cell count 
T. rubrum 
Table 4. Clinical presentation of onychomycosis in patients living with HIV/AIDS 
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 WSO PWSO 
Nail plate appearance Crumbly Normal 
White patches Ill defined, irregular shapes 
multifocal 
Distinct border 
Localization in nail plate Any part  Starts at the lunula 
Most frequent organism Trichophyton mentagrophytes Trichophyton rubrum 
Table 5. Differences between WSO and PWSO 
HIV seronegative population normally present onychomycosis in one or both first toenails, 
which differs from patients living with HIV, who present with an atypical number of nails 
involved, usually more than three, and the first toenails may not be involved.  Another 
important difference with open population is of course, the age group involved that is much 
younger if they are living with HIV infection. 
Another typical characteristic of these patients is that they report a very short evolution, 
even two or three weeks in which they witness the rapid change in the appearance of their 
nails. It is not rare to see involvement of both finger and toenails, adding up to 15 or more 
nails infected. Anyhow, toenail infection remains the main infected area. 
Candida spp., being a frequent opportunistic infectious agent of immunosuppressed 
patients, one could expect that candidal paronychia should be a common finding, but it is 
seldomly found in finger or toenails. 
WSO is mostly seen in toenails. The reason for the low incidence on fingernails could be that 
it is a relatively superficial infection that could easily be washed off. So, even in 
immunosuppressed patients, the finding of WSO in fingernails is rare (Figure 1). 
 
 
 
Fig. 1. White superficial onychomycosis 
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Clinically WSO is seen as opaque white scaly patches, ill defined, irregular and multifocal 
distributed along the dorsal surface of the nail plate. Each of these plaques corresponds to 
a fungal colony. Although this is a superficial infection, the nail plate surface looks 
affected. It is not smooth, but rather irregular and might even be porous and crumbly in 
some areas.   
WSO usually affects toenails, more frequently seen in the first, second and/or third nails. 
The association to interdigital tinea pedis is common. This clinical form may rapidly evolve 
to a more deep form of onychomycosis, particularly if associated in that or any other nail to 
PWSO or DLSO (Figure 2). 
 
 
Fig. 2. White superficial onychomycosis and proximal white subungual onychomycosis  
If paronychia is associated to WSO, it is generally due to infection of non-dermatophyte 
moulds (Piraccini & Tosti, 2004).  
PWSO is considered by many physicians “the hallmark” of HIV infection. It is certainly true 
that this clinical form became widely known because of the AIDS pandemia, and although 
this still remains a rare form of onychomycosis, immunosuppression should be suspected 
when observed.  
This clinical pattern initiates beneath the proximal nail fold, in the area of the lunula. A 
white, opaque and well defined macula is visible through the nail plate. The cuticle and 
other periungual tissues are unaffected. It may then continue to spread distally or may 
remain confined, although it will eventually grow out with the nail.  
The most important clinical feature to differentiate it from other invasion patterns is that the 
nail plate is smooth and looks unaltered in consistency and thickness.   
It is common to see different proportions of nail plates affected in the same individual. It can 
be seen either or in both finger and toenails. 
Besides these “classic” characteristics, PWSO may present in a variety of other forms. They 
may be longitudinal bands of leukonychia of varying thickness, isolated or multiple 
transverse white bands that may even be a little curved, similar to the natural curvature of 
the lunula (Figure 3). 
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Fig. 3. Proximal white subungual onychomycosis 
 
 
Fig. 4. Leukonychia in transversal bands 
As confirmed by histopathology, these transverse bands are separated by normal nail plate, 
clinically and histologically (Figure 4). Immunosuppressed patients frequently present rapid 
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development in several digits simultaneously. A study found statistical differences in the 
incidence of onychomycosis correlated with the stage of AIDS reported. It was of 21% in 
patients with stage A, 30% with patients in stage B, compared to 54% of patients in stage C 
(p<0.02) (Baran at al.,  2005) .  
With time, PWSO may evolve to cover the entire nail plate, the original macula may grow 
out (Figure 5), or DLSO or TDO may develop. These two last clinical presentations are 
common findings in longstanding onychomycosis infections.  
Despite this clinical modification of the appearance of the nail plate and worsening in the 
appearance of the nail, these infections don´t disseminate systemically to other organs other 
than the nail apparatus, and therefore, are not life threatening infections (Havlickova, 2008).  
 
 
Fig. 5. Proximal white subungual onychomycosis growing out with the nail plate 
5. Diagnosis 
Clinical diagnosis is the many used method by most physicians, particularly non-
dermatologists.  However, we do not recommend this as the sole method because only 50% 
of nail dystrophies correspond to onychomycosis, and treatment with oral antifungals 
should be restricted to those patients where it has been widely justified.  
The physical examination of the nails should be complemented with the medical history 
regarding sports habits such as swimming or running, because of the excessive humidity 
and repeated trauma to the nail apparatus respectively. 
In immunosuppressed patients, complete physical exploration should be performed. Several 
reports have mentioned that tinea capitis or tinea inguinale can be precursors of 
onychomycosis by autoinoculation.  
5.1 Laboratory tests 
5.1.1 Direct mounts 
Potassium hydroxide 10-20% (KOH) preparation and fungal culture in Sabouraud dextrose 
and/or Mycosel agar are the most known and used laboratory tests.  
KOH mounts have the enormous advantage that one can obtain the result immediately, 
even during the office visit of the patient. It is painless, non-invasive and has very low cost. 
The downside to it is that only trained dermatologists, microbiologists or mycologists will 
be able to recognize the fungal structures in the nail scrapings, and one must have a light 
microscope at hand.  
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Fig. 6. KOH preparation 40X 
The suggested technique for obtaining the sample for any type of onychomycosis is to clean 
the area with alcohol wipes, and scrape with a curette or a sterile scalpel blade the involved 
area of the nail. Part of the scale obtained is then placed in a slide with a drop of KOH and a 
coverslip. Slight heating of the slide’s bottom with a match for a few seconds will accelerate 
the separation of the keratinocytes, facilitating the sample’s observation. The rest of the scale 
will be used for culture. Of course, the clinical characteristics of the nail invasion will 
determine how the sample should be obtained.  
For WSO, we recommend the use of a scalpel blade that should be used to scrape uniformly 
the affected area of the nail plate.  
In the case of PWSO, the sampled area will depend on the localization of the white patch. 
When the leukonychia is proximal to the nail fold, a 15-scalpel blade is used to “drill” the 
dorsal area of the nail plate. We discard the first scales obtained, and save the ones from 
beneath. Much care should be placed in not perforating completely the nail plate’s thickness. 
This would cause bleeding and pain. When the white area is already growing out of the nail, 
and has reached the distal border, or the leukonychia involves the totality of the nail plate, 
the sample can be obtained with a small curette, with the technique applied to DLSO, that is, 
scraping the ventral portion in the free border of the nail plate.  
After the sample has been obtained and the mount prepared, the slide is placed in a light 
microscope and observed at 10X and 40X, where one can look for hyphae (Figure 6), 
arthroconidia or yeasts. In mycotic white nails fungal elements are usually abundant. After a 
few hours (3-4) the mount will no longer be useful. 
Chlorazol black E is an aid for fungal structure identification. It is an acid stain that binds 
chitin found in the fungal structures, and not in the keratinocytes. The hyphae and or spores 
are stained green-blue, facilitating their identification under a light microscope. Studies have 
found that using Chlorazol black is more cost effective than KOH. 
Clacofluor white is another stain employed for the identification of fungi in nail material. It 
binds to cellulose and chitin. It must be seen under a microscope with UV radiation 
(fluorescent) which are scarce and expensive. It is rarely used, but yields better results than 
KOH and Chlorazol black. 
The sensibility of KOH mounts has been estimated of 80% (66-95%) and specificity of 72%. 
(47-72%). Positive and negative predictive values are 88 and 58% respectively. These results 
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rely mainly on the experience of the observer, and despite the previously described 
inconvenience, it is still considered the gold standard for the diagnosis of onychomycosis. 
The sensibility for Chlorazol black has been reported of 94%, making it one of the most cost 
effective diagnostic tests for onychomycosis (Weinberg et al., 2003; Lilly et al., 2006).  
5.1.2 Cultures 
Culture is the gold standard for accurate identification of the pathogen involved but not for 
clinical diagnosis. It is routinely performed in mycology laboratories as well as the KOH 
examination.  
In the selection of the culture media we must consider that Sabouraud agar enables growth 
of dermatophytes but also of opportunistic fungi, and even bacteria. This is useful 
particularly when non-dermatophyte mould infection is suspected. Sabouraud plus 
Chloramphenicol and Actidione (Mycosel) is more specific for dermatophytes since the 
antibiotics added limit opportunistic and bacterial growth.  
The sample is the same as for direct examination. The scales are placed with sterile 
technique in Sabouraud dextrose and/or Mycosel agar. The media are incubated at 25°C 
and are checked for growth once a week during four weeks.  
The growth in cultures is observed macro and microscopically. Macroscopically, the number 
of colonies, color, texture, rate of growth, pigment production and other and characteristics 
of the strain are noted (Figure 7).  
 
 
Fig. 7. T. rubrum culture 
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For microscopic identification, mounts are prepared with lactophenol-cotton blue and 
observed for microconida, macroconidia, hyphae or spores that will enable us to identify the 
etiological agent (Figure 8).  
 
 
Fig. 8. T. rubrum 10X 
The correct identification of the fungal species causing onychomycosis will allow the correct 
selection of the antifungal treatment.   
The culture has a sensitivity of 59% (29-59%) and specificity of 82%. Between 30-50% of all 
cultures will grow, even with a positive direct examination, and it is important to recognize 
that this doesn’t mean that there is no fungal infection. Many factors determine if a culture 
will grow, such as the sample site and amount of scale taken, viability of the dermatophytes, 
inoculation technique and storage temperature.  
Correlation with KOH and clinical observations are fundamental for proper treatment and 
follow up. 
5.1.3 Molecular biology 
Some techniques such as polymerase chain reaction (PCR) are highly sensitive and specific 
for the identification of microorganisms such as fungi. The gene Chitin synthase 1 (CHS1) is 
shared by the three dermatophyte genera (Trichophyton, Epidermophyton and Microsporum) 
and can be evaluated in patients with onychomycosis.  
This test not only allows the positive identification of fungal elements, it also identifies the 
fungal species, dermatophytes, non dermatophyte molds or yeasts, even in patients taking 
oral antifungal treatment.  
PCR followed by restriction fragment length polymorphism (RFLP), real time PCR and 
multiplex PCR assay have been adapted for detection of dermatophytes in clinical specimens. 
Maybe in the future at least one of these tests will be the gold standard for diagnosis and 
fungal species identification. For the moment, these techniques are inaccessible except for 
some select investigative laboratories (Garg et al.,  2009).  
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5.2 Histopathology 
Nail plate or nail apparatus biopsy is rarely necessary for diagnosis, although it has been 
considered by some authors like the most sensitive and specific method for diagnosis. This 
could be true for those medical settings that lack a mycology laboratory.  
The histopathological information that exists regarding the different clinical patterns of 
fungal invasion of the nail plate has been useful for the clinical classification of 
onychomycosis and hopefully will help understand more of the physiopathology of the 
disease. 
Hematoxilin and eosin routine stain is performed, but the Peryodic Acid Schiff (PAS) 
staining technique is the most useful for this tissue (Figure 9). It easily enables the 
identification of the fungal structures where the hyphae and spores can be identified as 
eosinophillic structures mixed with the laminated keratinocytes that form the nail plate. 
 
 
Fig. 9. Fungal structures in nail plate. PAS 
The SWO has been identified as a superficial infection of the nail plate in most cases, and 
only rarely has been reported a “deep” SWO, involving as well the ventral aspect of the nail 
plate. The usual findings are hyphae and or spores in the dorsal aspect of the nail plate, 
generally confined to the upper half of the nail plate.  
Some authors have suggested that SWO is not always caused by primary dorsal penetration, 
supported on the fact that sometimes the nail invasion is beneath the upper half that may 
even reach the ventral aspect of the nail plate. This may depend on the fungal agent 
involved and its affinity towards keratin and the enzymes required for its destruction.  
The involvement in PWSO initiates and commonly remains localized to the ventral aspect of 
the nail, although progression to invasion of the entire nail plate thickness may also be seen.  
Histology of leukonychia in transversal bands demonstrates that the nail is invaded 
intermittently, with spared areas of healthy nail that correlate to the band of healthy nail 
observed clinically. This suggests that re-activation may be episodic in these cases (Baran et 
al., 2005; Moreno-Coutiño et al., 2010; Nandedkar et al., 2005).  
Apparently, the etiological agent does not vary the infection pattern in the nail plate. Similar 
findings have been reported in T. rubrum and M. canis infected nails, where all the nail plate, 
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from the matrix to the distal portion, shows invasion by numerous fungal elements, 
particularly in the ventral aspect of the nail plate.  
Piraccini et al. evaluated the nail bed, searching for fungal invasion as well, since the 
principal amount of fungi are found in the part of the nail plate that is in direct contact with 
the nail bed. The histology showed that there is no fungal invasion of this tissue, and is also 
devoid of inflammatory changes (Piraccini et al.), .  
Currently, the study of the nail plate by histology with PAS stain has been reported to have 
92% (85-98.85) of sensibility and 72% of specificity, with a positive and negative predictive 
value of 89.7% and 77% respectively.  
6. Treatment and outcome 
The treatment of onychomycosis, that is a chronic and mostly asymptomatic disease, 
sometimes is postponed by many reasons, either from part of the physician or the patient. 
However, immunocompromised patients such as those living with HIV, search for 
treatment due to psychosocial reasons. The burden of knowing themselves with the HIV 
infection, makes them extra-conscious of their appearance, beyond being esthetically 
acceptable, they seek a healthy appearance.  
To choose the adequate antifungal drug, one must consider several factors. Of course, the 
clinical pattern of onychomycosis is probably the most determinant of all, as will be 
discussed further. The number of nails involved and the percentage of affection, previous 
treatments for the fungal infection and for other diseases, allergies, and finally, the 
socioeconomic status is a very important factor in this group of patients. 
Recently, effective antimycotics, in particular terbinafine, was shown to enhance and restore 
cell-mediated immunity, which potentially improves the therapeutic outcome even for this 
group of patients 
Currently, three main strategies apply: topical, oral and combination treatment. Amorolfine 
nail lacquer and oral terbinafine are the most effective drugs as monotherapy. However, the 
best cure rates are obtained with a combination of oral and local therapy (Lecha et al. 2005). 
Clues to consider: 
1. Clinical pattern of onychomycosis 
As the name describes, WSO is superficial as the infection remains in the dorsal aspect of the 
nail plate. This is the only one that may be treated with topical medications such as a lacquer 
or by chemical avulsion of the nail plate. It is important to remember that transungual 
delivery of the drug is limited by the low permeability of the nail plate, so repeated dosing 
over a long period is required.  
It is a common finding that WSO is combined with any other clinical form of onychomycosis. 
In this case, the patient must be treated according to the most sever pattern shown. 
PWSO varies clinically depending on the time of the diagnosis. This onychomycosis initiates 
in the matrix area, and as the nail grows, the area involved may grow out too, or the disease 
may spread to affect the entire nail plate. For this clinical form, the recommended treatment 
approach is oral antimycotics, such as terbinafine or itraconazole. 
General guidelines state that oral treatment is indicated if the matrix area is involved and/or 
more than 50% of the nail plate is affected. 
2. Isolated fungi  
Specific identification of the fungal pathogen is useful for adequate prescription. 
Dermatophytes are successfully treated with terbinafine or itraconazole. However, NDM have 
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not shown a better cure rate if treated with oral anifungals. Terbinafine has no effect over 
Candida sp. infection, so in cases of paronychia, itraconazole is recommended Hogan, 2006). 
3. Socioeconomic status 
Antifungal medication, particularly oral and lacquer are very expensive, and should be 
administered continuously for several months. Before prescribing the antifungal, one must 
consider cost-benefit, availability and accessibility of the treatment.  
4. Comorbidities and other prescription drugs 
Most systemic antifungals potentially have interactions with other drugs. 
6.1 Antifungals 
6.1.1 Topical  
Lacquer  
Commercially three different antimycotics are available in lacquer. All of them show similar 
cure rates, but the continuous application is required for an average of 4 months (Sidou et al. 
2004; Sigurgeisson Ket al. 2010; Subissi et al. 2010). 
Amorolfine 5% 
Is a morpholine derivative with broad spectrum as antifungal agent, including dermatophytes, 
NDM, and yeasts.  It is fungicidal for most species. It rapidly penetrates the nail, and the 
clearance is slow because it is applied in a non-water soluble film that remains in the nail for a 
week. This drug is well tolerated and minor local adverse reactions are observed rarely. In 
vitro, apparently amorolfine synergizes with ketoconazole, griseofulvin and terbinafine.  
It is indicated once a week, approximately 6 months. This is the most recommended drug, 
since it has shown longer remanence on the nail surface, more resistance to chemical trauma 
from soaps and mechanical aggressions to the nail apparatus, and is the most cost-effective 
of the lacquers. It is safe and effective as prophylaxis of recurrence in these patients that 
relapse frequently. 
Ciclopirox 8%   
It has a broad spectrum drug including almost all of the clinically relevant dermatophytes, 
yeasts and moulds. It is active against azole-resistant Candida and even some bacteria. The 
main antimicrobial activity apparently is by inhibition of the metal dependent enzymes that 
are responsible for degradation of peroxides within the fungal cell. The fungal resistance to 
this drug is extremely low and shows a mild anti-inflammatory effect in biochemical and 
pharmacological models. It is considered to have high affinity to keratin and good nail 
permeation. As a topical drug, it is devoid of systemic adverse reactions. Mild erythema has 
seldom been reported (<5% treated patients). This lacquer must be applied every other day 
the first month, twice a week the second and once a week for one or two more months.  
Tioconazole 28% 
It is an imidazole with activity against moulds and yeasts. This is the least recommended 
because of its posology and limited effectiveness. The suggested dosage is twice a day 
during 6-12 months .  
Chemical avulsion 
Chemical destruction of the nail plate with occlusive 40% urea and bifonazole 1% is 
recommended for patients that have very thickened nail plate, dermatophytoma or when 
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oral therapy is contraindicated. It is also an effective and low cost adyuvant to oral therapy, 
particularly in cases of NMD infection or pediatric patients. 
Urea is a keratolytic that destroys hydrogen unions. This destruction allows the antifungal 
to penetrate deeply in the nail plate for better results. Bifonazole is a wide spectrum azolic 
derivate with activity against yeasts, dermatophytes and NDM,  lipophilic and hydrophobic 
that allows long cutaneous retention of the drug. It is applied under occlusion once a day 
and the softened nail plate must be removed before reapplying the medication. The most 
common side effects are local erosion and pain that remit when the treatment is suspended 
(Arenas, 2001¸Carrillo-Muñoz et al. 2010). 
6.1.2 Systemic (oral) 
Terbinafine  
This antimycotic is by far the most widely prescribed oral medication because of its low 
incidence of drug interactions compared to azoles. Terbinafine is an allylamine that reaches 
steady-state in the nail matrix and bed in one week, and plasma levels in 10-14 days. 
Because of its keratinophilic and lipophilic characteristics, this dug persists in the nail 
apparatus for 24-156 days.  
It is fungicidal and fungistatic, with broad spectrum for moulds. Its absorption is not 
affected by food, is metabolized extensively in the liver and excreted principally in urine. 
The terminal half life is of 16-22 hr. that may be prolonged in patients with liver or renal 
impairment, particularly those with <50 mL/min of creatinine clearance or >300 μMol/ of 
serum creatinine.  The most recognized drug interactions are with cimetidine and rifampin. 
Terbinafine also inhibits the cytochrome P4502D6 (CYP2D6) so caution is recommended 
when administering CYP2D6 substrates. 
The mycological cure rate has been reported 48-90% on different trials, and has always been 
superior in comparison to placebo, itraconazole, griseofulvin and fluconazole. Only one case 
of T. rubrum resistant to terbinafine has been published. 
It can be administered daily 250 mg/3-4 months, or in pulses, 250 mg twice a day for one 
week each month at least during four months.  
No drug interactions have been observed in patients living with HIV/AIDS in several 
reports (Elewski & Tavakkol, 2005; Osborne et al. 2006).  
Itraconazole 
This is a fungistatic drug that diffuses through the matrix and nail bed 3-12 weeks, but then 
these levels are sustained in the nail plate for several months. It is well tolerated, and less 
than 3% of the patients report adverse effects. The most common are headache and 
gastrointestinal symptoms. In skin, rash and pruritus have been seldomly reported. 
It is better absorbed if taken with food. It´s absorption is reduced by antacids as omeprazole, 
cimetidine and ranitidine. Because this drug is metabolized in the liver by CYP3A4, the 
potential for interaction with other drugs is important to consider. Its prescription is 
contraindicated with antidysrhymics, antimalarials, benzodiapines, antipsychotic and 
statins. Serum levels of warfarin, cisapride and cyclosporine should be monitored in 
concomitant therapy. Concurrent administration with antidiabetic drugs may cause 
hypoglycemia. Liver enzyme elevations are reported in 0.3-0.5%. 
Specifically in patients living with HIV/AIDS, is important to remember that rifampin and 
other antituberculous drug may vary serum levels of itraconazole. Protease inhibitors also 
inhibit CYP3A4, and a dose reduction of itraconazole may be required.  
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However, despite all the contraindications and precautions, itraconazole is effective in 
clearing onychomycosis as well as systemic fungal infections commonly seen in this group 
of patients, so in clinical practice, itraconazole dosage is frequently adjusted to cure both 
fungal diseases. 
The recommended dose for onychomycosis is 200 mg/day or 200 mg twice a day for one 
week during four months. 
Fluconazole  
This is another azole, with similar mode of action and drug interactions than itraconazole. It 
is widely prescribed as prophylaxis for opportunistic fungal infections in 
immunosuppressed patients Nonetheless, it is not recommended for onychomycosis 
treatment, since terbinafine and itraconazole have better cure rates in shorter periods. 
6.2 Combination therapy 
The combination of topical and systemic treatment increases antifungal spectrum, fungicidal 
activity and safety. It also reduces treatment duration.  
Any lacquer or urea may be combined with systemic antifungals such as terbinafine or 
itraconazole. The decision must be made considering the clinical pattern, number of nails 
involved, general health status of the patient and accessibility to the drugs. 
Many trials have reported the outcome of combination therapy. The most successful ones 
are those that include terbinafine or itraconazole. One of them reported that the combination 
of amorolfine and terbinafine had a 59% success rate compared to 45% in the group of oral 
terbinafine only. Treatment cost was lower in the combination group. Other combinations 
find similar results. 
Another approach is the combination of oral antifungal with surgical avulsion of the 
infected nail. One of us has reported a better response rate, combining with terbinafine in 
pulses. However, we do not recommend this technique as first line of treatment, because it 
is invasive, painful, and must be preformed by a nail surgery expert (Baran et al. 2007; 
Domínguez-Cherit et al. 1999).  
6.3 Observation  
For patients that recently initiated antiretroviral therapy (ARV) we recommend observation 
for approximately six months. This obeys to several reasons. First of all, because they must 
accept and tolerate the ARV medications and its side effects which almost all patients refer. 
Even though most are mild and transient they must adequate their life style to them and 
wait for the majority of adverse effects to disappear. Another reason is that in our clinical 
practice, we have observed several times that these patients clinically improve, that is, the 
area of onychomycosis is reduced, or even cure completely by allowing the immune system 
restoration with ARV therapy (Tachikawa, et al.1999). 
7. Differential diagnosis 
Differential diagnosis should be done with any other cause of leukonychia.  The list is long 
and includes congenital and acquired diseases. Among the most common causes in the 
HIV/AIDS infected patients include frequent  skin diseases as dyshidrosis or erythema 
multiforme, systemic acute infections such as pneumonia, herpes zoster, or even 
intoxication with lead, antimony, fluoride, androgen therapy, cirrhosis, hyperalbuminemia, 
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gout, protein deficiency, kidney transplant and renal failure either acute or chronic, 
parathyroid insufficiency, Hodgkin´s disease and intra-abdominal malignancies, cachectic 
state, peripheral neuropathy, shock, surgery and drugs such as hydroxyurea.  
8. Conclusions 
Fungal leukonychia is common in patients living with HIV/AIDS or those that have any 
other cause of immunosuppression. However, OSDL continues to be the most prevalent 
presentation of onychomycosis. 
The findings of PWSO or SWO are not synonymous of HIV infection, but should alert the 
physician of that possibility. 
Patients with HIV infection present onychomycosis in a more extensive manner, involving 
many nails simultaneously and with rapid evolution. This is apparently directly related to a 
decline in the immune system function.  
An adequate approach to diagnosis will allow the best evaluation of each particular case, 
and on that basis, decide the best option of treatment for the patient. Ideally, every patient 
must be evaluated by a dermatologist who will take the scales for a KOH direct examination 
and a mycological culture. 
The direct exam with KOH or Chlorazol Black is the best. test for diagnosis and most cost-
effective. It should be complemented with a culture, although the possibility of a negative 
result is high. When the diagnosis is not clear after these tests, or a mycology laboratory is 
inaccessible, a biopsy of the nail plate, stained with PAS can be performed with high 
sensibility and specificity for diagnosis.  
To determine the treatment, we must always keep in mind the general state and 
socioeconomic situation. This will allow us to choose the best option in each case.   
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